Follow
Jesse Zaretsky
Jesse Zaretsky
UCLA
Verified email at wustl.edu
Title
Cited by
Cited by
Year
Genetic basis for clinical response to CTLA-4 blockade in melanoma
A Snyder, V Makarov, T Merghoub, J Yuan, JM Zaretsky, A Desrichard, ...
New England Journal of Medicine 371 (23), 2189-2199, 2014
44712014
Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma
W Hugo, JM Zaretsky, LU Sun, C Song, BH Moreno, S Hu-Lieskovan, ...
Cell 165 (1), 35-44, 2016
30162016
Mutations associated with acquired resistance to PD-1 blockade in melanoma
JM Zaretsky, A Garcia-Diaz, DS Shin, H Escuin-Ordinas, W Hugo, ...
New England Journal of Medicine 375 (9), 819-829, 2016
29642016
Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression
A Garcia-Diaz, DS Shin, BH Moreno, J Saco, H Escuin-Ordinas, ...
Cell reports 19 (6), 1189-1201, 2017
16422017
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ...
Cancer discovery 7 (2), 188-201, 2017
11692017
Genetic mechanisms of immune evasion in colorectal cancer
CS Grasso, M Giannakis, DK Wells, T Hamada, XJ Mu, M Quist, JA Nowak, ...
Cancer discovery 8 (6), 730-749, 2018
4212018
PD-1 blockade expands intratumoral memory T cells
A Ribas, DS Shin, J Zaretsky, J Frederiksen, A Cornish, E Avramis, E Seja, ...
Cancer immunology research 4 (3), 194-203, 2016
4022016
Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction
DK Wells, MM van Buuren, KK Dang, VM Hubbard-Lucey, KCF Sheehan, ...
Cell 183 (3), 818-834. e13, 2020
3492020
High response rate to PD-1 blockade in desmoplastic melanomas
Z Eroglu, JM Zaretsky, S Hu-Lieskovan, DW Kim, A Algazi, DB Johnson, ...
Nature 553 (7688), 347-350, 2018
3062018
Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017; 7: 188–201. doi: 10.1158/2159-8290
DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ...
CD-16-1223.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0
251
Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells
B Homet Moreno, JM Zaretsky, A Garcia-Diaz, J Tsoi, G Parisi, L Robert, ...
Cancer immunology research 4 (10), 845-857, 2016
1512016
T cell antigen discovery via trogocytosis
G Li, MT Bethune, S Wong, AV Joglekar, MT Leonard, JK Wang, JT Kim, ...
Nature methods 16 (2), 183-190, 2019
1362019
T cell antigen discovery via signaling and antigen-presenting bifunctional receptors
AV Joglekar, MT Leonard, JD Jeppson, M Swift, G Li, S Wong, S Peng, ...
Nature methods 16 (2), 191-198, 2019
1332019
Overcoming genetically based resistance mechanisms to PD-1 blockade
DY Torrejon, G Abril-Rodriguez, AS Champhekar, J Tsoi, KM Campbell, ...
Cancer discovery 10 (8), 1140-1157, 2020
1062020
PAK4 inhibition improves PD-1 blockade immunotherapy
G Abril-Rodriguez, DY Torrejon, W Liu, JM Zaretsky, TS Nowicki, J Tsoi, ...
Nature Cancer 1 (1), 46-58, 2020
1042020
Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma
A Kalbasi, M Tariveranmoshabad, K Hakimi, S Kremer, KM Campbell, ...
Science translational medicine 12 (565), eabb0152, 2020
902020
Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov. 2018; 8: 730–749. doi: 10.1158/2159-8290
CS Grasso, M Giannakis, DK Wells, T Hamada, XJ Mu, M Quist, JA Nowak, ...
CD-17-1327.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0
85
Sensitive detection and analysis of neoantigen-specific T cell populations from tumors and blood
S Peng, JM Zaretsky, AHC Ng, W Chour, MT Bethune, J Choi, A Hsu, ...
Cell reports 28 (10), 2728-2738. e7, 2019
782019
PD-1 blockade expands intratumoral memory T cells. Cancer Immunol. Res. 2016; 4: 194–203. doi: 10.1158/2326-6066
A Ribas, DS Shin, J Zaretsky, J Frederiksen, A Cornish, E Avramis, E Seja, ...
CIR-15-0210.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0
71
Tumor characteristics associated with benefit from pembrolizumab in advanced non–small cell lung cancer
S Hu-Lieskovan, A Lisberg, JM Zaretsky, TR Grogan, H Rizvi, DK Wells, ...
Clinical cancer research 25 (16), 5061-5068, 2019
632019
The system can't perform the operation now. Try again later.
Articles 1–20